This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams, W. G., Deaver, K. A., Cochi, S. L., Plikaytis, B. D., Zell, E. R., Broome, C. V., & Wenger, J. D.(1993). Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA, 269, 221–226.
Adegbola, R. A., Mulholland, E. K., Secka, O., Jaffar, S., & Greenwood, B. M. (1998). Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J. Infect. Dis., 177, 1758–1761.
Anderson, E. L., Kennedy, D. J., Geldmacher, K. M., Donnelly, J., & Mendelman, P. M. (1996). Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr., 128, 649–653.
Arden, N. H., Patriarca, P. A., & Kendal, A. P. (1986). Experience in the use and efficacy of inactivated influenza vaccine in nursing homes, in: Options for the Control of Influenza (A. P. Kendal & P. A. Patriarca, eds.). New York: Alan R. Liss, pp. 155–165.
Austrian, R., & Gold, J. (1964). Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med., 60, 759–776.
Austrian, R., Douglas, R. M., Schiffman, G., Coetzee, A. M., Koornhof, H. J., Hayden-Smith, S., & Reid, R. D. (1976). Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians, 89, 184–189.
Barbour, M. L., Mayon-White, R. T., Coles, C., Crook, D. W. M., & Moxon, E. R. (1995). The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J. Infect. Dis., 171, 93–98.
Belshe, R. B., Mendelman, P. M., Treanor. J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwell, K., Lacuzio, D., & Wolff, M. (1998). The efficacy of live attenuated, cold-adapted, trivalent, intranasal infiuenzavirus vaccine in children. N. Engl. J. Med., 338, 1405–1412.
Black, S., Shinefield, H., Ray, P., Lewis, E., Fireman, B., The Kaiser Permanente Vaccine Study Group, Austrian, R., Siber, G., Hackell, J., Kohberger, R., & Chang, I. H. (1998). Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of The Northern California Kaiser Permanente Efficacy Trial. Program of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California. Abstract LB-9.
Breiman, R. F., Butler, J. C., & McInnes, P. (1999). Vaccines to prevent respiratory infection: Opportunities on the near and far horizons. Curr. Opin. Infect. Dis., 12, 145–152.
Brichacek, B., Swindells, S., Janoff, E. N., Pirruccello, S., & Stevenson, M. (1996). Increased plasma human immuno-deficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis., 174, 1191–1199.
Briles, D. E., Hollingshead, S. K., Swiatlo, E., Brooks-Walter, A., Szalai, A., Virolainen, A., McDaniel, L. S., Benton, K. A., White, P., Prellner, K., Hermansson, A., Aerts, P. C., van Dijk, H., & Crain, M. J. (1997). PspA and PspC: Their potential for use as pneumococcal vaccines. Microb. Drug Resist., 3, 401–408.
Bush, C. E., Donovan, R. M., Markowitz, N. P., Kvale, P., & Saravolatz, L. D. (1996). A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. AIDS Hum. Retrovirol, 13, 23–26.
Butler, J. C., Breiman, R. P., Campbell, J. F., Lipman, H. B., Broome, C. V, & Facklam, R. R. (1993). Polysaccharide pneumococcal vaccine efficacy: An evaluation of current recommendations. JAMA, 270, 1826–1831.
Butler, J. C., Breiman, R. F., Lipman, H. B., Hofmann, J., & Facklam, R. R. (1995). Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for develop-ment of a conjugate vaccine. J. Infect. Dis., 171, 885–889.
Centers for Disease Control and Prevention (1997a). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 46(RR-8), 1–24.
Centers for Disease Control and Prevention (1997b). Outbreaks of pneumococcal pneumonia among unvaccinated resi-dents in chronic-care facilities—Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May–June 1996. MMWR, 46, 60–62.
Centers for Disease Control and Prevention (1998). Progress toward eliminating Haemophilus influenzae type b disease among infants and children-United States, 1987–1997. MMWR, 47, 993–998.
Centers for Disease Control and Prevention (1999). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 48(RR-4), 1–28.
Centers for Disease Control and Prevention (2000). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 49(RR-3), 1–38.
Chan, C. Y., Molrine, D. C., George, S., Tarbell, N. J., Mauch, P., Diller, L., Shamberger, R. C., Phillips, N. R., Goorin, A., & Ambrosino, D. M. (1996). Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccines after treatment of Hodgkin’s Disease. J. Infect. Dis., 173, 256–258.
Chenoweth, A., Waltz, A. D., Stokes, J. Jr. (1936). Active immunization with the viruses of human and swine influenza. Am. J. Dis. Child., 52, 757–758.
Clark, A., Potter, C. W., Jennings, R., Nicholl, J. P., Langrick, A. F., Schild, G. C., Wood, J. M., & Tyrrell, D. A. (1983). A comparison of live and inactivated influenza A (H1N1) virus vaccines: 2. Long-term immunity. J. Hyg., 90, 361–370.
Clemens, J. D., & Shapiro, E. D. (1984). Resolving the pneumo-coccal vaccine controversy: are there alternatives to ran-domized clinical trials? Rev. Infect. Dis., 6, 589–600.
Clemens, J., Brenner, R., Rao, M., Tafari, N., & Lowe, C. (1996). Evaluation of new vaccines for developing countries: Efficacy or effectiveness? JAMA, 275, 390–397.
Clements, M. L., & Stephens, I. (1997). New and improved vaccines against influenza, in: New Generation Vaccines, 2nd ed. (M. M. Levine, G. C. Woodrow, J. B. Kaper, & G. S. Cobon, eds.). New York: Marcel Decker, pp. 545–570.
Couch, R. B., Kasel, J. A., Glezen, W. P., Cate, T. R., Six, H. R., Taber, L. H., Frank, A. L., Greenberg, S. B., Zahradnik, J. M., & Keitel, W. A. (1986). Influenza: Its control in persons and populations. J. Infect. Dis., 153, 431–440.
Couch, R. B., Keitel, W. A., & Cate, T. R. (1997). Improvement of inactivated influenza virus vaccines. J. Infect. Dis., 176(Suppl. I),S38–S44.
Cox, N. J., Brammer, T. L., & Regnery, H. L. (1994). Influenza: Global surveillance for epidemic and pandemic variants. Eur. J. Epidemiol., 10, 467–470.
Davenport, F. M. (1961). Inactivated influenza virus vaccines: past, present, and future. Am. Rev. Respir. Dis., 83(Suppl), 146–150.
Davidson, M., Bulkow, L. R., Grabman, J., Parkinson, A. J., Chamblee, C, Williams, W. W., Lanier, A. P., & Schiffman, G. (1993). Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch. Intern. Med., 154, 2209–2214.
de Bruijn, I. A., Remarque, E. J., der Zijde, C. M. J., van Tol, M. J. D., Westendrop, R. G. J., & Knock D. L. (1999). Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis., 179, 31–36.
Deroo, T., Jou, W. M., & Fiers, W. (1996). Recombinant neuraminidase vaccine protects against lethal influenza. Vac-cine, 14, 561–569.
DeStefano, F., Goodman, R. A., Noble, G. R., McClary, G. D., Smith, S. J., & Broome, C. V. (1982). Simultaneous administration of influenza and pneumococcal vaccines. JAMA, 247, 2551–2554.
Douglas, R. M., Paton, J. C., Duncan, S. J., & Hansman, D. J. (1983). Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis., 148, 131–137.
Dowdle, W. R. (1981). Influenza immunoprophylaxis after 30 years’ experience, in: Genetic Variation among Influenza Viruses (D. P. Nayak, ed.). New York: Academic Press, pp. 525–534.
Dudas, R. A., & Karron, R. A. (1998). Respiratory syncytial virus vaccines. Clin. Microbiol. Rev., 11, 430–439.
Edwards, K. M., Dupont, W. D., Westrich, M. K., Plummer, W. D. Jr., Palmer, P. S., & Wright, P. F. (1994). A randomized controlled trial of cold-adapted and inactivated vaccines for prevention of influenza A disease. J. Infect. Dis., 169, 68–76.
Fair, B. M., Johnston, B. L., Cobb, D. K., Fisch, M. J., German-son, T. P., Adal, K. A., & Anglim, A. M. (1995). Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch. Intern. Med., 155, 2336–2340.
Fedson, D. S., Wajda, A., Nicol, J. P., Hammond, G. W., Kaiser, D. L., & Roos, L. L. (1993). Clinical effectiveness of influenza vaccination in Manitoba. JAMA, 270, 1956–1961.
Fedson, D. S., Musher, D. M., & Eskola, J. (1999). Pneumococcal vaccine, in: Vaccines, 3rd ed. (S. A. Plotkin & W. A. Orenstein, eds.). Philadelphia: W. B. Saunders Co., pp. 553–607.
Fine, M. J., Smith, M. A., Carson, C. A., Meffe, F., Sankey, S. S., Weisfeld, L. A., Detsky, A. S., & Kapoor, W. N. (1994). Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch. Intern. Med., 154, 2666–2677.
Fiore, A. E., Elliott, J. A., Franklin, A. R., Facklam, R. R., & Butler, J. C. The Pneumococcal Sentinel Surveillance Working Group. Pneumococcal polysaccharide vaccine ef-fectiveness among children of ages 2 though 5. Infectious Disease Society of America 35th Annual Meeting, Septem-ber 15, 1997, San Francisco, California. Abstract 615.
Fiore, A. E., Iverson, C.. Messmer, T., Erdman, D., Lett, S. M., Talkington, D. F., Anderson, L. J., Fields, B., Carlone, G. M., Breiman, R. F., & Cetron, M. S. (1998). Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J. Am. Geriatr. Soc., 46, 1112–1117.
Forrester, H. L., Jahnigen, D. W., & LaForce, F. M. (1987). Inefficacy of pneumococcal vaccine in a high-risk popula-tion. Am. J. Med., 83, 425–430.
Foster, D. A., Talsma, A., Fururnoto-Dawson, A., Ohmit, S. E., Margulies, J. R., Arden, N. H., & Monto, A. (1992). Influenza vaccine effectiveness in preventing hospitalizations for pneumonia in the elderly. Am. J. Epidemiol., 136, 296–307.
Francis, T. Jr., Salk, J. E., Pearson, H. E., & Brown, P. N. (1945). Protective efficacy of vaccination against induced influ-enza. J. Clin. Invest., 24, 536–546.
Fuller, J. D., Craven, D. E., Steger, K. A., Cox, N., Heeren, T. C., & Chernoff, D. (1999). Influenza vaccination of human immunodeficiency virus (HlV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin. Infect. Dis., 28, 541–547.
Gaillat, J., Zmirou, D., Mallaret, M. R., Rouhan, D., Bru, J. P., Stahl, J. P., Delormas, P., & Micoud, M. (1985). Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution. Rev. Epìdém. Santé Publ, 33, 437–444.
Glezen, W. P. (1996). Emerging infections: pandemic influenza. Epidemiol. Rev., 18, 64–76.
Glezen, W. P., & Couch, R. B. (1978). Interpandemic influenza in the Houston area, 1974–76. N. Engl. J. Med., 298, 587–592.
Go, E. S., & Ballas, Z. K. (1996). Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J. Allergy Clin. Immunol., 98, 205–215.
Govaert, T. M. E., Dinant, G. J., Aretz, K., Masurel, N., Sprenger, M. J. V., Knottnerus, J. A. (1993). Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. Br. Med. J., 307, 988–990.
Govaert, T. M., Thijs, C. T., Masurel, N., Sprenger, M. J., Dinant, G. J., & Knottnerus, J. A. (1994). The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA, 272, 1661–1665.
Gross, S P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995). The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Intern. Med., 123, 518–527.
Gross, P. A., Russo, C., Dran, S., Cataruozolo, P., Munk, G., & Lancey, S. C. (1997). Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin. Diagn. Lab. Immunol., 4, 491–492.
Gruber, W. C., Belshe, R. B., King, J. C., Treanor, J. J., Piedra, P. A., Wright, P. F., Reed, G. W., Anderson, E., & Newman, F. (1996). Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J. Infect. Dis., 173, 1313–1319.
Hilleman, M. R., Carlson, A. J., McLean, A. A., Vella, P. P., Weibel, R. E., & Woodhour, A. F. (1981). Streptococcus pneumoniae polysaccharide vaccine: age and dose re-sponses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev. Infect. Dis., 3(Suppl.), S31–S42.
Jackson, L. A., Benson, P., Sneller, V.-P., Butler, J. C., Thompson, R. S., Chen, R. T, Lewis, L. S., Carlone, C., De-Stefano, F., Holder, P., Lezhava, T., & Williams, W. W. (1999). Safety of revaccination with pneumococcal poly-saccharide vaccine. JAMA, 281, 243–248.
Jacobs, G. G., Johnson, J. L., Boom, W. H., Wallis, R. S., Whalen, C. C., & Ginsberg, A. M. (1997). Tuberculosis vaccines: How close to human testing? Tuber. Lung Dis., 78, 159–169.
James, J. M., Zeiger, R. S., Lester, M. R., Fasano, M. B., Gern, J. E., Mansfield, L. E., Schwartz, H. J., Sampson, H. A., Windom, H. H., Machtinger, S. B., & Lensing, S. (1998). Safe administration of influenza vaccine to patients with egg allergy. J. Pediatr., 133, 624–628.
Kaplan, J. E., Katona, P., Hurwitz, E. S., & Schonberger, L. B. (1982). Guillain-Barré syndrome in the United States, 1979–1980 and 1980–1981: lack of an association with influenza vaccination. JAMA, 248, 698–700.
Katzenstein, T. L., Gerstoft, J., & Nielsen, H. (1996). Assessments of plasma HIV RNA and CD4 cell counts after combined Pneumovax® and tetanus toxoid vaccination: No detectable increase in HIV replication 6 weeks after immunization. Scand. J. Infect. Dis., 28, 239–241.
Kaufman, P. (1947). Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study. Arch. Intern. Med., 79, 518–531.
Käyhty, H., Ahman, H., Rönnberg, P.-R., Tillikainen, R., & Eskola, J. (1995). Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis., 172, 1273–1278.
Keitel, W. A., Cate, T. R., Couch, R. B., Huggins, L. L., & Hess, K. R. (1997). Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine, 15, 1114–1122.
Kilbourne, E. D. (1994). Inactivated influenza vaccines, in: Vaccines, 2nd ed. (S. A. Plotkin & E. A. Mortimer, Jr., eds.). Philadelphia: W. B. Saunders and Company, pp. 565–581.
Koivula, I., Stén, M., Leinonen, M., & Mäkelä, P. H. (1997). Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am. J. Med., 103, 281–290.
Koskela, M., Leinonen, M., HNivN, V. M., Timonen, M., & Mäkelä, P. H. (1986). First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr. Infect. Dis., 5, 45–50.
Kraus, C., Fischer, S., Ansorg, R., & Hüttemann, U. (1985). Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination. Med. Microbiol. Immunol., 174, 51–58.
Laboratory Centre lor Disease Control (1998). Canadian Immunization Guide, 5th ed. Ottawa: Canadian Medical Association.
Lakey, D. L., Treanor, J. J., Belts, R. R, Smith, G. E., Thompson, J., Sannella, E., Reed, G., Wilkinson, B. E., & Wright, P. F. (1996). Recombinant baculovirus influenza A hemagglutinín vaccines are well tolerated and ímmunogeníc in healthy adults. J. Infect. Dis., 174, 838–841.
Langmuir, A. D., Bregman, D. J., Kurland, L. T, Nathanson, N., & Victor, M. (1984). An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am. J. Epidermiol., 119, 841–879.
Lasky, T, Terracciano, G. J., Magder, L., Koski, C. L., Ballesteros, M., Nash, D., Clark, S., Haber, P., Stolley, P. D., Schonberger, L. B., & Chen, R. T. (1998). The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med., 339, 1797–1802.
Leinonen, M., Säkkinen, A., Kalliokoski, R., Luotonen, J., Timonen, M., & Mäkelä, P. H. (1986). Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr. Infect. Dis., 5, 39–44.
Lock, R. A., Paton, J. C., & Hansman, D. (1988). Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb. Path.. 5, 461–467.
Maassab, H. F., Kendal, A. P., & Davenport, F. M. (1972). Hybrid formation of influenza virus at 25°. Proc. Soc. Exp. Biol Med., 139, 768–773.
MacLeod, C. M., Hodges, R. G., Heidelberger, M., & Bernhard, W. G. (1945). Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med., 82, 445–465.
Margolis, K. L., Nichol, K. L., Poland, G. A., & Pluhar, R. E. (1990). Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA, 264, 1139–1141.
Marríe, T. J. (1994). Community-acquired pneumonia. Clin. Infect. Dis., 18, 501–515.
Marston, B. J., Plouffe, J. F., File, T. M., Hackman, B. A., Salstrom, S. J., Lipman, H. B., Kolczak, M. S., & Breiman, R. F. (1997). Incidence of community-acquired pneumonia requiring hospitalization: results of population-based active surveillance in Ohio. Arch. Intern. Med., 157, 1709–1718.
McDaniel, L. S., Sheffield, J. S., Delucchi, P., & Briles, D. E. (1991). PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect. Immun., 59, 222–228.
McDaniel, L. S., Loechel, F., Benedict, C., Greenway, T., Briles, D. E., Conry, R. M., & Curiel, D. T. (1997). Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. Gene Ther., 4, 375–377.
Meiklejohn, G. (1983). Viral respiratory disease at Lowry Air Force Base in Denver. 1952–82. J. Infect. Dis., 148, 775–784.
Minor, D. R., Schiffman, G., & McIntosh, L. S. (1979). Response of patients with Hodgkin’s disease to pneumococcal vaccine. Ann. Intern. Med., 90, 887–892.
Molrine, D. C., George, S., Tarbell, N., Mauch, P., Diller, L., Neuberg, D., Shamberger, R. C., Anderson, E. L., Phillips, N. R.. Kinsella, K., & Ambrosino, D. M. (1995). Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin’s disease. Ann. Intern. Med., 123, 828–834.
Mufson, M. A., Krause, H. E., Schiffman, G., & Hughey, D. F. (1987). Pneumococcal antibody levels one decade after immunization of healthy adults. Am. J. Med. Sci., 293, 279–284.
Murphy, B. R. (1993). Use of live attenuated cold-adapted influenza A reassortant vaccines in infants, children, young adults and elderly adults. Infect. Dis. Clin. Pract., 2, 174–181.
Murphy, B. R., Hall, S. L., Kulkarni, A. B., Crowe, J. E. Jr., Collins, P. L., Connors, M., Karron, R. A., & Chanock, R. M. (1994). An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res., 32, 13–36.
Murphy, K. R., & Strunk, R. C. (1985). Safe administration of influenza vaccine in asthmatic children sensitive to egg protein. J. Pediatr., 106, 931–933.
Musher, D. M., Groover, J. E., Rowland, J. M., Watson, D. A., Struewing, J. B., Baughn, R. E., & Mufson, M. A. (1993). Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis., 17, 66–73.
Musher, D. M., Groover, J. E., Watson, D. A., Pandey, J. P., Rodriguez-Barradas, M. C., Baughn, R. E., Pollack, M. S., Graviss, E. A., de Andrade, M., & Amos, C. I. (1997). Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J. Invest. Med., 45, 57–68
National Center for Health Statistics. (1998). Health, United States, 1998 with Socioeconomic Status and Health Chartbook. Hyattsville, MD: National Center for Health Statistics, p. 212.
Nayak, A. R., Tinge, S. A., Tart, R. C., McDaniels, L. S., Briles, D. E., & Curtiss, R. III. (1998). A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. Immun., 66, 3744–3751.
Neuzil, K. M., Reed, G. W., Mitchel, E. F., & Griffin, M. R. (1999). Influenza-associated morbidity and mortality in young and middle-aged women. JAMA, 281, 901–907.
Nichol, K. L., Margolis, K. L., Wuorenma, J., & von Sternberg, T. (1994). The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med., 331, 778–784.
Nichol, K. L., Lind, A., Margolis, K. L., Murdoch, M., McFadden, R., Hauge, M., Magnan, S., & Drake. M. (1995). The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med., 333, 889–893.
Nichol, K. L., Margolis, K. L., Lind, A., Murdoch, M., McFadden, R., Hauge, M., Magnan, S., & Drake, M. (1996). Side effects associatedwith influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch. Intern. Med., 156, 1546–1550.
Nichol, K. L., Wuorenma, J., & von Sternberg, T. (1998). Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med., 158, 1769–1776.
Noble, G. R. (1982). Epidemiological and clinical aspects of influenza, in: Basic and Applied Influenza Research (A. S. Beare, ed.). Boca Raton, FL: CRC Press, pp. 11–50.
Nuorti, J. P., Butler, J. C., Crutcher, J. M., Guevara, R., Welch, D., Holder, P., & Elliott, J. A. (1998). An outbreak of pneumonia and bacteremia due to multidrug-resistant Streptococcus pneumoniae among unvaccinated nursing home residents. N. Engl. J. Med., 338, 1861–1868.
O’Brien, K. L., Steinhoff, M. C., Edwards, K., Keyserling, H., Thoms, M. L., & Madore, D. (1996). Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr. Infect. Dis. J., 15, 425–430.
O’Brien, W. A., Grovit-Ferbas, K., Namazi, A., Ovcak-Derzic, S., Wang, H.-J., Park, J., Yeramian, C., Mao, S.-H., & Zack, J. A. (1995). Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood, 86, 1082–1089.
O’Dempsey, T. J. D., McArdle, T., Ceesay, S. J., Banya, W. A. S., Demba, E., Secka, O., Leinonen, M., Käyhty, H., Francis, N., & Greenwood, B. M. (1996). Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine, 14, 963–970
Office of Technology Assessment. (1981). Cost-effectiveness of Influenza Vaccination. Washington, DC: United States Congress.
Olsen, G. W., Burris, J. M., Burlew, M. M., Steinberg, M. E., Patz, N. V., Stoltzfus, J. A., & Mandel, K. H. (1998). Absenteeism among employees who participated in a workplace influenza immunization program. J. Occupat. Environ. Med., 40, 311–316.
örtqvist, A., Hedlund, J., Burman, L. A., Eibel, E., Höfer, M., Leinonen, M., Lindblad, I., Sundelöf, B., Kalin, M., & Swedish Pneumococcal Vaccination Study Group. (1998). Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people. Lancet, 351, 399–403.
Patriarca, P. A., & Cox, N. J. (1997). Influenza pandemic preparedness for the United States. J. Infect. Dis., 176(Suppl. 1), S4–S7.
Plouffe, J. F., Breiman, R. F., & Facklam, R. R. (1996). Bacteremia with Streptococcus pneumoniae in adults—Implications for therapy and prevention. JAMA, 275, 194–198.
Powers, D. C., Anderson, E. L., Lottenbach, K., & Mink, C. M. (1996). Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis., 173, 1014–1018.
Rennels, M. B., Edwards, K. M., Keyserling, H. L., Reisinger, K. S., Hogerman, D. A., Madore, D. V., Chang, I., Paradiso, P. R., Malinoski, F. J., & Kimura, A. (1998). Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics, 101, 604–611.
Robinson, H. L., Boyle, C. A., Feltquate, D. M., Morin, M. J., Santoro, J. C., & Webster, R. G. (1997). DNA immunization for influenza virus: Studies using hemagglutinin-and nucleoprotein-expressing DNAs. J. Infect. Dis., 176(Suppl. 1), S50–S55.
Rodriquez-Barradas, M. C., Musher, D. M., Lahart, C., Lacke, C., Groover, J., Watson, D., Baughn, R., Cate, T., & Crofoot, G. (1992). Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis., 165, 553–556.
Romero-Steiner, S., Libutti, D., Pais, L. B., Dykes, J., Anderson, P., Whitin, J. C., Keyserling, H. L., & Carlone, G. M. (1997). Standardization of an opsonophagocytic assay of the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol., 4, 415–422.
Romero-Steiner, S., Musher, D. M., Cetron, M. S., Pais, L. B., Groover, J. E., Fiore, A. E., Plikaytis, B. D., & Carlone, G. M. (1999). Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis., 29, 281–288.
Safrin, S., Rush, J. D., & Mills, J. (1990). Influenza in patients with human immunodeficiency virus infection. Chest, 98, 33–37.
Sampson, J. S., Furlow, Z., Whitncy, A. M., Williams, D., Facklam, R., & Carlone, G. M. (1997). Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes. Infect. Immun., 65, 1967–1971.
Sankilampi, U., Honkanen, P. O., Bloigu, A., & Leinonen, M. (1997). Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis., 176, 1100–1104.
Schmid, G. P., Smith, R. P., Baltch, A. L., Hall, C. A., & Schiffman, G. (1981). Antibody response to pneumococcal vaccine in patients with multiple myeloma. J. Infect. Dis., 143, 590–597.
Schoendorf, K. C., Adams, W. G., Kiely, J. L., & Wenger, J. D. (1994). National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991. Pediatrics, 93, 663–668.
Scholtissek, C. (1994). Source for influenza pandemics. Eur. J. Epidemiol., 10, 455–458.
Shapiro, E. D., Berg, A. T., Austrian, R., Schroeder, D., Parcells, V, Margolis, A., Adair, R. K., & Clemens, J. D. (1991). The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med., 325, 1453–1460.
Siber, G. R. (1994). Pneumococcal disease: prospects for a new generation of vaccines. Science, 265, 1385–1387.
Simberkoff, M. S., Cross, A. P., Al-lbrahim, M., Baltch, A. L., Geiseler, P. J., Nadler, J., Richmond, A. S., Smith, R. P., Schiffman, G., Shepard, D. S., & van Eeckhout, J. P. (1986). Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med., 315, 1318–1327.
Simonsen, L., Clarke, M. J., Williamson, D., Stroup, D. F., Arden, N. H., & Schonberger, L. B. (1997). The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Pub. Health, 87, 1944–1950.
Simonsen, L., Clarke, M. J., Schonberger, L. B., Arden, N. H., Cox, N. J., & Fukuda, K. (1998). Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis., 178, 53–60.
Sims, R. V., Steinmann, W. C., McConville, J. H., King, L. R., Zwick, W. C., & Schwartz, J. S. (1988). The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med., 108, 653–657.
Sisk, J. E., Moskowitz, A. J., Whang, W., Fedson, D. S., McBean, A. M., Plouffe, J. E, Cetron, M. S., & Butler, J. C. (1997). Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA, 278, 1333–1339.
Smit, P., Oberholzer, D., Hayden-Smith, S., Koornhof, H. J., & Hilleman, M. R. (1977). Protective efficacy of pneumococcal polysaccharide vaccines. JAMA, 238, 2613–2616.
Sniadack, D. H., Schwartz, B., Lipman, H., Bogaerts, J., Butler, J. C., Dagan, R., Echaniz-Aviles, G., Lloyd-Evans, N., Fenoll, A., Guirguis, N., Henrichsen, J., Klugman, K., Lehmann, D., Takala, A. K., Vandepitte, J., Gove, S., & Breiman, R. F. (1995). Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr. Infect. Dis. J., 14, 503–510.
Stanley, S. K., Ostrowski, M. A., Justement, J. S., Gantt, K., Hedayati, S., Mannix, M., Roche, K., Schwartzentruber, D. J., Fox, C. H., & Fauci, A. S. (1996). Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type I. N. Engl. J. Med., 334, 1222–1230.
Steinhoff, M. C., Edwards, K., Keyserling, H., Thoms, M. L., Johnson, C., Madore, D., & Hogerman, D. (1994). A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J., 13, 368–372.
Takala, A. K., Eskola, J., Leinonen, M., Kayhty, H., Nissinen, A., Pekkanen, E., & Mäkela, P. H. (1991). Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis., 164, 982–986.
Treanor, J. J., Betts, R. F., Smith, G. E., Anderson, E. L., Hackett, C. S., Wilkinson, B. E., Belshe, R. B., & Powers, D. C. (1996). Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis., 173, 1476–1470.
USPHS/IDSA Prevention of Opportunistic Infections Working Group. (1997). Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann. Intern. Med., 127, 922–946.
Vella, P. P., McLean, A. A., Woodhour, A. F., Weibel, R. E., & Hilleman, M. R. (1980). Persistence of pneumococcal antibodies in human subjects following vaccination. Proc. Soc. Exp. Biol. Med., 164, 435–438.
Vernacchio, L., Neufield, E. J., MacDonald, K., Kurth, S., Murakami, S., Hohne, C., King, M., & Molrine, D. (1998). Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J. Pediatr., 133, 275–278.
Webster, R. G. (1998). Influenza: an emerging disease. Emerg. Infect. Dis., 4, 436–441.
Webster, R., Bean, W., German, O., Chambers, T., & Kawaoka, Y. (1992). Evolution and ecology of influenza A viruses. Microbiol. Rev., 56, 152–179.
Whalen, R. G. (1996). DNA vaccines for emerging infectious diseases: what if? Emerg. Infect. Dis., 2, 168–175.
Wilde, J. A., McMillan, J. A., Serwint, J., Butta, J., O’Riordan, M. A., & Steinhoff, M. C. (1999). Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA, 281, 909–913.
Wright, A. E., Morgan, W. P., Cantab, M. B., Colebrook, L., Lond, M. B., Dodgson, R. W., & Lond, M. D. (1914). Observations on prophylactic inoculations against pneumococcus infection, and on the results which have been achieved by it. Lancet, 1, 87–95.
Wu, H.-Y., Nahm, M. H., Guo, Y, Russell, M. W., & Briles, D. E. (1997). Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis., 175, 839–846.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Butler, J.C., Fukuda, K., Breiman, R.F. (2002). Prevention of Community-Acquired Pneumonia. In: Marrie, T.J. (eds) Community-Acquired Pneumonia. Springer, Boston, MA. https://doi.org/10.1007/0-306-46834-4_14
Download citation
DOI: https://doi.org/10.1007/0-306-46834-4_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46432-4
Online ISBN: 978-0-306-46834-6
eBook Packages: Springer Book Archive